公开(公告)号：US20250009871A1

公开(公告)日：2025-01-09

申请号：US18564932

申请日：2022-05-30

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  KUNMING INSTITUTE OF ZOOLOGY, CHINESE ACADEMY OF SCIENCES

Inventor： Likun GONG ,  Jin REN ,  Wei HUANG ,  Yong GAN ,  Yongtang ZHENG ,  Jianhua SUN ,  Xinxin ZHANG ,  Yiru LONG ,  Qiuping QIN ,  Tingting LIU ,  Feng TANG ,  Pan YU ,  Yunqiu MIAO ,  Yonglong CAI ,  Mian QIN ,  Tianzhang SONG

IPC: A61K39/215 ,  A61K9/107 ,  A61P37/04 ,  C07K14/005

Abstract: Disclosed are an application of a coronavirus SARS-CoV-2 vaccine polypeptide, a polypeptide composition and a nanoemulsion preparation thereof in the prevention of coronavirus SARS-CoV-2 wild and mutant strain infections. Specifically, provided is a coronavirus SARS-CoV-2 vaccine polypeptide having an amino acid sequence derived from an S protein of SARS-CoV-2 wild and mutant strains, the vaccine polypeptide can enable the body to generate high-level and durable humoral immune responses against SARS-CoV-2 and to produce high titers of RBD-binding antibodies and neutralizing antibodies that block the binding of RBD to ACE2. The vaccine polypeptide can be used to prevent infections of SARS-CoV-2 wild strain and B.1.1.7, B.1.351, B.1.617, B.1.1.529 and other mutant strains.

公开(公告)号：US20240197900A1

公开(公告)日：2024-06-20

申请号：US18278302

申请日：2022-02-22

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Wei HUANG ,  Feng TANG ,  Wei SHI ,  Shang JIAO ,  Siqi WANG

IPC: A61K47/68 ,  A61P35/00 ,  C12N9/04 ,  C12N9/24 ,  C12P19/12

CPC classification number: A61K47/68031 ,  A61K47/68033 ,  A61K47/6883 ,  A61K47/6889 ,  A61P35/00 ,  C12N9/0006 ,  C12N9/2402 ,  C12P19/12 ,  C12Y101/03009 ,  C12Y302/01169

Abstract: The present application relates to a disaccharide linker, a disaccharide-small molecule drug conjugate and a sugar chain fixed-point antibody-drug conjugate, a preparation method and the use thereof. The structure of the disaccharide linker is as shown in the following formula I. The present invention provides a new-type fixed-point and quantitative antibody-drug conjugate form, and the stability and cytotoxicity of the antibody-drug conjugate are improved.

公开(公告)号：US20240261391A1

公开(公告)日：2024-08-08

申请号：US18565013

申请日：2022-05-30

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  SHENZHEN UNIVERSITY

Inventor： Xinxin ZHANG ,  Likun GONG ,  Jin REN ,  Guangyi JIN ,  Wei HUANG ,  Yong GAN ,  Jianhua SUN ,  Tingting LIU ,  Yiru LONG ,  Yunqiu MIAO ,  Qiuping QIN ,  Feng TANG ,  Pan YU ,  Linmiao GUO

IPC: A61K39/215 ,  A61K39/00 ,  A61K47/22 ,  C12N7/00

CPC classification number: A61K39/215 ,  A61K47/22 ,  C12N7/00 ,  A61K2039/55566 ,  C12N2770/20034

Abstract: The present invention relates to a novel coronavirus vaccine using a TLR7 agonist conjugated peptide as an antigen and an emulsion as an adjuvant. An antigen polypeptide of the conjugated peptide is a polypeptide derived from an S protein of SARS-COV-2, and the adjuvant is an oil-in-water nanoemulsion containing squalene. The conjugated peptide nanoemulsion vaccine preparation of the present invention is thermally stable, and can induce a high level of protective humoral immune response in a cynomolgus monkey, and the neutralizing antibody titer of antiserum after immunization of cynomolgus monkey is high, such that invasion of wild-type strain and mutant novel coronavirus can be blocked. The vaccine of the present invention has a nearly complete protection effect on the upper and lower respiratory tracts of the cynomolgus monkey in a cynomolgus monkey SARS-COV-2 challenge test. The nanoemulsion vaccine of the present invention is fast and convenient to prepare, and can realize large-scale production in a short term for coping with the novel coronavirus outbreak.

公开(公告)号：US20230241204A1

公开(公告)日：2023-08-03

申请号：US18008826

申请日：2020-12-01

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  SHENZHEN UNIVERSITY

Inventor： Likun GONG ,  Jin REN ,  Guangyi JIN ,  Wei HUANG ,  Qiuping QIN ,  Yiru LONG ,  Jianhua SUN ,  Tingting LIU ,  Feng TANG ,  Peng ZHU

IPC: A61K39/215 ,  A61P31/14

CPC classification number: A61K39/215 ,  A61P31/14 ,  A61K2039/60

Abstract: Disclosed are a polypeptide vaccine coupled with a TLR7 agonist for novel coronavirus and the use thereof. Specifically, the present invention provides a vaccine polypeptide for novel coronavirus pneumonia based on the basis of the analytical study of the RBD sequence and structural information of the S protein of SARS-CoV-2, wherein the vaccine polypeptide has the following structural formula: Z-(J-U)n, where in the formula, Z, J, U, n, etc. are as defined in the description. Also provided in the present invention are a vaccine composition containing the vaccine polypeptide and the use thereof.